Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Dalia A Gaber, Abeer I Alburaykan, Lama M Alruthea, Njoud S Aldohan, Raneem F Alharbi, Alhanoof R Aljohani, Helah M Albilaihi & Somaiah S Adogim. (2022) Development, in vitro Evaluation, and in vivo Study of Adhesive Buccal Films for the Treatment of Diabetic Pediatrics via Trans Mucosal Delivery of Gliclazide. Drug Design, Development and Therapy 16, pages 4235-4250.
Read now
Read now
Brian Tomlinson, Nivritti Gajanan Patil, Manson Fok, Paul Chan & Christopher Wai Kei Lam. (2022) The role of sulfonylureas in the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 23:3, pages 387-403.
Read now
Read now
Samreen Jahan, Mohd. Aqil, Abdul Ahad, Syed Sarim Imam, Ayesha Waheed, Abdul Qadir & Asgar Ali. (2022) Nanostructured lipid carrier for transdermal gliclazide delivery: development and optimization by Box-Behnken design. Inorganic and Nano-Metal Chemistry 0:0, pages 1-14.
Read now
Read now
Articles from other publishers (21)
Ashok Kumar Das, Banshi Saboo, Rajeev Chawla, S. R. Aravind, Rajesh Rajput, Awadhesh K. Singh, J. J. Mukherjee, Ashok Jhingan, Parag Shah, Vaishali Deshmukh, Shailaja Kale, Shalini Jaggi, G. R. Sridhar, Rajnish Dhediya & Kumar Gaurav. (2023) Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach. International Journal of Diabetes in Developing Countries 43:6, pages 856-874.
Crossref
Crossref
Yujun Zhao, Jianfeng Lou, Yuhang Lu, Feilong Zhou & Ziqin Yan. 2023. Privileged Scaffolds in Drug Discovery. Privileged Scaffolds in Drug Discovery
65
80
.
André J. Scheen. 2023. Diabetes and Cardiovascular Disease. Diabetes and Cardiovascular Disease
895
921
.
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, Andreas Filippaios, Elliot Sternthal, Niki Katsiki & Christos Mantzoros. (2022) Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism 137, pages 155332.
Crossref
Crossref
Ke Wang, Aimin Yang, Mai Shi, Claudia C. H. Tam, Eric S. H. Lau, Baoqi Fan, Cadmon K. P. Lim, Heung Man Lee, Alice P. S. Kong, Andrea O. Y. Luk, Brian Tomlinson, Ronald C. W. Ma, Juliana C. N. Chan & Elaine Chow. (2021)
CYP2C19
Loss‐of‐function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 Diabetes
. Clinical Pharmacology & Therapeutics 111:2, pages 461-469.
Crossref
Crossref
Yousef Al-Saleh, Shaun Sabico, Ahmed Al-Furqani, Amin Jayyousi, Dalal Alromaihi, Ebtesam Ba-Essa, Fatheya Alawadi, Juma Alkaabi, Mohamed Hassanein, Saud Al-Sifri, Seham Saleh, Thamer Alessa & Nasser M. Al-Daghri. (2021) Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas. Diabetes Therapy 12:8, pages 2115-2132.
Crossref
Crossref
Yang Cheng, Kezuo Hou, Yizhe Wang, Yang Chen, Xueying Zheng, Jianfei Qi, Bowen Yang, Shiying Tang, Xu Han, Dongyao Shi, Ximing Wang, Yunpeng Liu, Xuejun Hu & Xiaofang Che. (2021) Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma. Frontiers in Oncology 11.
Crossref
Crossref
Cem Haymana, Alper Sonmez, Ibrahim Demirci, Guzin Fidan Yaylalı, Irfan Nuhoglu, Seda Sancak, Murat Yilmaz, Yuksel Altuntas, Nevin Dinccag, Tevfik Sabuncu, Fahri Bayram & Ilhan Satman. (2021) Patterns and preferences of antidiabetic drug use in Turkish patients with type 2 diabetes – A nationwide cross-sectional study (TEMD treatment study). Diabetes Research and Clinical Practice 171, pages 108556.
Crossref
Crossref
André J. Scheen. (2021) Sulphonylureas in the management of type 2 diabetes: To be or not to be?. Diabetes Epidemiology and Management 1, pages 100002.
Crossref
Crossref
Ioannis Ilias, Costas Thomopoulos, Helena Michalopoulou, George Bazoukis, Costas Tsioufis & Thomas Makris. (2020) Antidiabetic drugs and blood pressure changes. Pharmacological Research 161, pages 105108.
Crossref
Crossref
Jing Du, Nanno Kleefstra, Dennis Schrijnders, Klaas H. Groenier, Geertruida H. de Bock & Gijs W.D. Landman. (2020) Is Gliclazide Associated with a Lower Obesity-Related Cancer Risk Compared to Other Sulfonylureas? A Long-term Prospective Cohort Study. Cancer Epidemiology, Biomarkers & Prevention 29:8, pages 1596-1605.
Crossref
Crossref
S. J. Wood, D. J. Magliano, J. S. Bell, J. E. Shaw, C. S. Keen & J. Ilomäki. (2019) Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?. Diabetic Medicine 37:8, pages 1367-1373.
Crossref
Crossref
Ravi Kant, Ramesh Babu Bodla, Garima Kapoor & Rubina Bhutani. (2019) Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design. Bioorganic Chemistry 91, pages 103111.
Crossref
Crossref
Maja Ðanić, Bojan Stanimirov, Nebojša Pavlović, Saša Vukmirović, Jelena Lazić, Hani Al-Salami & Momir Mikov. (2019) Transport and Biotransformation of Gliclazide and the Effect of Deoxycholic Acid in a Probiotic Bacteria Model. Frontiers in Pharmacology 10.
Crossref
Crossref
Weiheng Wen, Jinru Gong, Peili Wu, Min Zhao, Ming Wang, Hong Chen & Jia Sun. (2019) Mutations in gliclazide‐associated genes may predict poor bladder cancer prognosis. FEBS Open Bio 9:3, pages 457-467.
Crossref
Crossref
A.J. Scheen. (2018) Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies. Diabetes & Metabolism 44:5, pages 386-392.
Crossref
Crossref
André J. Scheen. (2018) GLP-1 receptor agonists and cardiovascular protection: A class effect or not?. Diabetes & Metabolism 44:3, pages 193-196.
Crossref
Crossref
Momir Mikov, Maja Đanić, Nebojša Pavlović, Bojan Stanimirov, Svetlana Goločorbin-Kon, Karmen Stankov & Hani Al-Salami. (2017) Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics. European Journal of Drug Metabolism and Pharmacokinetics 43:3, pages 269-280.
Crossref
Crossref
Sanjay Kalra, Silver Bahendeka, Rakesh Sahay, Sujoy Ghosh, Fariduddin Md, Abbas Orabi, Kaushik Ramaiya, Sameer Al Shammari, Dina Shrestha, Khalid Shaikh, Sachitha Abhayaratna, PradeepK Shrestha, Aravinthan Mahalingam, Mazen Askheta, AlyAhmed A. Rahim, Fatimah Eliana, HariK Shrestha, Sandeep Chaudhary, Nancy Ngugi, JeanClaude Mbanya, ThanThan Aye, TintSwe Latt, ZhanayA Akanov, AbbasRaza Syed, Nikhil Tandon, AG Unnikrishnan, SV Madhu, Ali Jawa, Subhankar Chowdhury, Sarita Bajaj & AshokKumar Das. (2018) Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force. Indian Journal of Endocrinology and Metabolism 22:1, pages 132.
Crossref
Crossref
Shaukat Sadikot, K. Jothydev, A.H. Zargar, Jamal Ahmad, S.R. Arvind & Banshi Saboo. (2017) Clinical practice points for diabetes management during RAMADAN fast. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, pages S811-S819.
Crossref
Crossref
Mariona Nadal Llover & Montse Cols Jiménez. (2017) Hacia una mejor atención a los pacientes: medicamentos a evitar y posibles alternativas. Actualización 2016-2017. FMC - Formación Médica Continuada en Atención Primaria 24:6, pages 338-351.
Crossref
Crossref